Loading...
Bilateral Trade Intelligence · $10 Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $10 worth of pharmaceutical formulations from Ghana across 1 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are AZIDUS LABORATORIES GHANA ($10). The leading products are Plasma ($10). Average shipment value: $10.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Plasma | $10 | 100.0% |
India imports 1+ pharmaceutical formulations from Ghana with a combined trade value of $10. Key products include Plasma ($10). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 1 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Ghana, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Ghana buyers, regulatory requirements, and logistics for that specific product corridor. Products include Plasma ($10) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Ghana. Leading exporters include Azidus Laboratories Ghana, . The top exporter accounts for 100.0% of total India–Ghana pharma exports. Source: Indian Customs (DGFT).
1 companies in Ghana import pharmaceutical formulations from India. Top buyers include Azidus Laboratories Limited, . The largest buyer accounts for 100.0% of India–Ghana pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Ghana and India has remained relatively underdeveloped from 2022 to 2026. Between 2022 and 2026, India imported a total of $10 worth of finished pharmaceutical formulations from Ghana, comprising a single shipment of plasma. This limited trade volume indicates minimal engagement in this sector during the specified period.
Ghana's contribution to India's pharmaceutical imports is negligible, accounting for only $10 over the 2022-2026 period. The sole product imported was plasma, highlighting Ghana's minimal presence in India's pharmaceutical import landscape.
Between 2024 and 2026, there were no significant policy changes, trade agreements, or regulatory harmonization efforts by the Central Drugs Standard Control Organisation (CDSCO) that impacted the pharmaceutical trade between Ghana and India. The lack of substantial trade activity suggests limited bilateral engagement in this sector during this timeframe.
Registration process, GMP requirements, import documentation
For Ghanaian companies aiming to export pharmaceutical products to India, obtaining registration with the CDSCO is mandatory. The process involves several key steps:
1. Online Application: Applicants must visit the CDSCO SUGAM portal and create an account by providing necessary details such as applicant type, username, password, and contact information.
2. Form Submission: After account activation, applicants need to submit the appropriate form (e.g., Form 40 for importers) along with required documents, including identity proof, address proof, and an undertaking as specified by CDSCO.
3. Verification and Approval: Once submitted, the application undergoes verification by CDSCO officials. This may involve site inspections and consultations with subject-matter experts to assess the safety and efficacy of the products.
4. License Issuance: Upon successful evaluation, CDSCO grants the necessary licenses, authorizing the import and distribution of the pharmaceutical products in India.
The entire process can take several months, depending on the complexity of the application and the regulatory requirements.
India requires that pharmaceutical products imported from Ghana adhere to Good Manufacturing Practices (GMP) standards. Manufacturing sites in Ghana must be WHO-GMP certified to ensure compliance with international quality standards. CDSCO may conduct inspections to verify adherence to these standards before granting import licenses.
To import pharmaceutical products into India, Ghanaian companies must provide several key documents:
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Ghana to India are limited, with plasma being the only product imported during the 2022-2026 period. This indicates a lack of diversity in the types of pharmaceutical products traded between the two countries.
Given the minimal trade volume, there is no significant importation of innovator drugs, novel formulations, or advanced therapies from Ghana to India. The trade is restricted to a single product category, plasma, without diversification into other pharmaceutical specialties.
The negligible import demand from Ghana to India can be attributed to several factors:
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
These tariffs and taxes collectively impact the pricing and competitiveness of imported pharmaceutical products in the Indian market.
As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Ghana concerning pharmaceutical imports. India's participation in regional agreements like the Regional Comprehensive Economic Partnership (RCEP) does not currently include Ghana, limiting the scope for preferential trade terms in the pharmaceutical sector.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and restricts the patentability of new forms of known substances unless they demonstrate enhanced efficacy. This provision may affect the importation of certain pharmaceutical products from Ghana. Additionally, the National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines in India, which can influence the pricing strategies of imported drugs.
Shipping routes, port infrastructure, cold chain compliance
The limited pharmaceutical trade between Ghana and India results in minimal shipping activity. For the single shipment of plasma, the most likely route would involve sea freight from Ghana's ports to major Indian ports, such as Mumbai or Chennai. Transit times would vary depending on the specific ports and shipping schedules but are generally in the range of 20-30 days.
Ghana's primary export ports include Tema and Takoradi, which handle a significant portion of the country's maritime trade. In India, major import ports include Mumbai, Chennai, and Kolkata, equipped with facilities to handle pharmaceutical imports. However, the minimal trade volume between Ghana and India suggests limited utilization of these ports for such transactions.
For pharmaceutical imports, Indian customs procedures require compliance with CDSCO regulations, including product registration and quality testing. Cold chain management is critical for temperature-sensitive products like plasma. Importers must ensure that the entire logistics chain adheres to Good Distribution Practices (GDP) to maintain product integrity upon arrival in India.
Market size, healthcare system, growth outlook
Despite being a major pharmaceutical manufacturer, India imports certain specialized products not produced domestically. However, the negligible import volume from Ghana indicates that India does not currently rely on Ghana for these specialized pharmaceutical products.
The limited trade suggests that Ghanaian pharmaceutical companies have minimal presence in the Indian market. There are no significant strategies, local partnerships, or contract manufacturing arrangements reported between Ghanaian companies and Indian entities in the pharmaceutical sector.
India's "Atmanirbhar Bharat" initiative and the Production Linked Incentive (PLI) scheme aim to boost domestic manufacturing and reduce import dependency. These policies are likely to further diminish the need for pharmaceutical imports from countries like Ghana, potentially leading to a decline or substitution of such imports in the future.
Competing origins, India's edge, challenges and threats
India's pharmaceutical imports are predominantly sourced from countries like the United States, European Union nations, China, Switzerland, and Japan. Ghana's share in this import landscape is negligible, with the single shipment of plasma in 2022-2026 representing a minuscule fraction compared to imports from these other countries.
While Ghana may offer competitive pricing and quality in certain pharmaceutical products, the lack of significant trade suggests that Indian buyers do not perceive substantial advantages in sourcing from Ghana. Factors such as established trade relationships, regulatory compliance, and product availability from other countries likely outweigh any potential benefits from Ghanaian imports.
Indian pharmaceutical manufacturers are continually developing alternatives to imported products, including biosimil
India exported pharmaceuticals worth $10 to Ghana across 1 verified shipments.
1. AZIDUS LABORATORIES GHANA — $10. Total: 1 suppliers.
1. AZIDUS LABORATORIES LIMITED — $10. 1 buyers total.
1. Plasma ($10, 100.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $10 corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$10 per consignment across 1 shipments.
1 Indian companies. Largest: AZIDUS LABORATORIES GHANA with $10.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 1 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists